Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab
Authors' conclusion
About one-quarter of patients with RA experienced DP, which responded well to sarilumab.
Study context
- Population
- RA patients in phase 3 randomized controlled trials (RCTs) MOBILITY, TARGET and MONARCH and their open-label extensions (OLEs); DP defined as TJC28 − SJC28 ≥71,531 sarilumab 200 mg patients from RCTs
- Comparison
- Sarilumab 200 mg vs placebo or adalimumab 40 mg, in patients with and without disproportionate articular pain
- Sarilumab 200 mgn = 1,531
Methodological detailspooled data from phase 3 RCTs (MOBILITY, TARGET, MONARCH)
- Pooled data from phase 3 RCTs (MOBILITY, TARGET, MONARCH)
Primary result
As reported in the abstract
Prevalence of baseline disproportionate articular pain (DP)
Sarilumab 200 mg
23%
353 of 1531
Further findings
Low disease activity in RCTs
- More sarilumab-treated patients achieved low disease activity vs comparators, regardless of baseline DP status
DP status in OLEs
- Patients more likely to lose rather than gain DP status
Original publication
Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab. Rheumatology (Oxford). Published 22 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →